- Home
- IMCR vs AVPT Comparison
IMCR vs AVPT Comparison
Compare IMCR & AVPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- AVPT
- Stock Information
- Founded
- IMCR 2008
- AVPT 2001
- Country
- IMCR United Kingdom
- AVPT United States
- Employees
- IMCR N/A
- AVPT N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- AVPT Computer Software: Prepackaged Software
- Sector
- IMCR Health Care
- AVPT Technology
- Exchange
- IMCR Nasdaq
- AVPT Nasdaq
- Market Cap
- IMCR 1.6B
- AVPT 3.8B
- IPO Year
- IMCR 2021
- AVPT N/A
- Fundamental
- Price
- IMCR $35.05
- AVPT $18.51
- Analyst Decision
- IMCR Buy
- AVPT Buy
- Analyst Count
- IMCR 10
- AVPT 5
- Target Price
- IMCR $58.13
- AVPT $17.40
- AVG Volume (30 Days)
- IMCR 322.9K
- AVPT 1.2M
- Earning Date
- IMCR 08-07-2025
- AVPT 08-07-2025
- Dividend Yield
- IMCR N/A
- AVPT N/A
- EPS Growth
- IMCR N/A
- AVPT N/A
- EPS
- IMCR N/A
- AVPT N/A
- Revenue
- IMCR $333,581,000.00
- AVPT $349,012,000.00
- Revenue This Year
- IMCR $26.82
- AVPT $23.89
- Revenue Next Year
- IMCR $8.15
- AVPT $17.91
- P/E Ratio
- IMCR N/A
- AVPT N/A
- Revenue Growth
- IMCR 25.75
- AVPT 21.70
- 52 Week Low
- IMCR $23.15
- AVPT $9.38
- 52 Week High
- IMCR $41.54
- AVPT $20.25
- Technical
- Relative Strength Index (RSI)
- IMCR 58.09
- AVPT 49.14
- Support Level
- IMCR $32.20
- AVPT $17.78
- Resistance Level
- IMCR $35.69
- AVPT $19.05
- Average True Range (ATR)
- IMCR 1.29
- AVPT 0.55
- MACD
- IMCR 0.29
- AVPT -0.09
- Stochastic Oscillator
- IMCR 81.93
- AVPT 37.24
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About AVPT AvePoint Inc.
AvePoint Inc provides customizable solutions to optimize SaaS operations, enable secure collaboration, and accelerate digital transformation across technologies and industries. Its Confidence Platform delivers a comprehensive set of cloud-based solutions enabling IT operations, development operations, and cybersecurity professionals to monitor and secure the digital workplace using SaaS tools.